Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FLPAE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,357
Award facts
- Contract value 100% obligated
- $11,357.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,357.40 by the Defense Logistics Agency on July 25, 2025, for the supply of Nucala 100 mg/ml auto-injectors. This delivery order was issued without a set-aside designation and is expected to be completed by July 28, 2025, with performance occurring at the vendor's Park Ridge location. The award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
Nucala (mepolizumab) is a biologic treatment typically used for severe eosinophilic asthma and other eosinophilic conditions, and its inclusion in this delivery order reflects DMS Pharmaceutical Group's role as a critical supplier of specialty medications and biologics to military health facilities. The vendor has demonstrated consistent success in federal pharmaceutical procurement through its established portfolio of delivery orders covering diverse medical products from the Defense Logistics Agency, positioning the company as a key distributor in the federal pharmaceutical supply chain serving DoD healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FLPAE?
SPE2DB25FLPAE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 25, 2025.
How much is contract SPE2DB25FLPAE worth?
The government has obligated $11,357 on SPE2DB25FLPAE.
Is contract SPE2DB25FLPAE an order under another contract?
Yes. SPE2DB25FLPAE is a delivery order under SPE2DB25D9302, an indefinite delivery contract.
Was contract SPE2DB25FLPAE competed?
The extent of competition for SPE2DB25FLPAE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award